Recent News and Articles on the Keywords: new + 739 + 0.36  Related to the article below (Last Update: 8/7/2008)

Earthtimes (press release) NBT Bancorp Inc. Announces Second Quarter Earnings of $0.45 per ... MarketWatch - Jul 28, 2008 This increase was due primarily to an increase in expenses related to the five new branches the Company has opened within the past eight months. ... BNCCORP, Inc. Reports Net Income of $700 Thousand, or $0.21 Per ... Earthtimes (press release) all 882 news articles »  OTC:BNCC - NBTB Petrolifera Petroleum reports Q2 2008 results and schedules ... Canada NewsWire (press release), Canada - Follow-up drilling on the two new pool crude oil discoveries at Puesto Morales x-1082 and Puesto Morales Este x-1002 will take priority to establish the ...TSE:PDP - BOM:500312 Monaco Coach Corporation Reports Second Quarter Results CNNMoney.com - Jul 30, 2008 "We are pleased that the current bank group has granted the waiver for the second quarter and that they are working with the Company as we complete our new ...MNC WELT ONLINE First Niagara Financial Group Reports 2008 Second Quarter Results MSN Money - Jul 24, 2008 ... of total assets 0.35% 0.36% 0.30% 0.27% Allowance for credit losses to total loans 1.23% 1.25% 1.23% 1.24% Allowance for credit losses to non-performing ... FirstMerit Reports Second Quarter 2008 EPS of $0.36 Per Share Trading Markets (press release) all 1,034 news articles »  FMER - FNFG - OTC:CMTX Nektar Therapeutics Announces Second Quarter 2008 Results Earthtimes (press release), UK - Included in the $70.9 million of overall research and development spending is approximately $32 million of new investments in Nektar's preclinical and ...NKTR Bryn Mawr Bank Corporation Reports Increase in Second Quarter ... StreetInsider.com (subscription), MI - Jul 24, 2008 The increase in non-interest expense is primarily the result of the increase in salaries and wages associated with the new growth initiatives, ...BMTC TOP Ships Reports Second Quarter and First Half 2008 Financial Results Earthtimes (press release), UK - Jul 31, 2008 Two of the vessels have already been delivered and the remaining three are expected to be delivered to their new owners by the end of August 2008 . ...TOPS SY Bancorp Announces Record Quarterly Per Share Results as Diluted ... StreetInsider.com (subscription), MI - Jul 16, 2008 All of these factors bode well for the Company's fundamental performance in the future and serve to counter the near-term impact of our expansion to new ... MBT Financial Corp. Announces Second Quarter 2008 Earnings istockAnalyst.com, OR - Jul 17, 2008 The Company undertakes no obligation to update or clarify forward-looking statements, whether as a result of new information, future events or otherwise. ...MBTF - KIDS - MROE

Selective inhibitors of mPGES-1, a new class of anti-inflammatory drugs that might lessen chance of COX-2 cardiovascular events

Researchers at the University of Pennsylvania School of Medicine have clarified the mechanism by which drugs like Celebrex and Vioxx cause heart problems, in multiple animal models.

The findings offer the prospect of a new generation of anti-inflammatory drugs that bypass this issue.

Ever since the association of selective inhibitors of COX-2 – Vioxx ( Rofecoxib ), Bextra ( Valdecoxib ), and Celebrex ( Celecoxib ) - with an increased incidence of heart attack and stroke, there has been intense interest in understanding the mechanism involved. Clarification of this issue offers the prospect of conserving the clinical benefit of these drugs for patients with arthritis, while managing the risk.

Almost 10 years ago, FitzGerald noticed that both Celebrex and Vioxx depressed in healthy individuals a protective fat called prostacyclin, while leaving unaltered a harmful one called thromboxane. This led him to predict that drugs in this class might confer a cardiovascular risk before either reached the US market.

In the study, published in the Journal of Clinical Investigation, the researchers used multiple genetically manipulated mice - including mice that mimicked the impact of either COX-2 inhibitors or low-dose aspirin and compared them with treating healthy mice with COX-2 inhibitors.

They found that genetic disruption of COX-2; inhibition of the enzyme by different inhibitors; and disruption of effects of prostacyclin by removing its receptor all had the same effect - a predisposition to clotting and an elevation of blood pressure.

The researchers also addressed the likely benefit of adding Aspirin to diminish this effect of the inhibitors. Surprisingly, this appeared to reduce not only the clotting response, but also the rise in blood pressure caused by COX-2 inhibitors.

A surprising finding came when the researchers turned to a drug target that might substitute for COX-2 - an enzyme called microsomal prostaglandin E synthase ( mPGES )-1.
Other studies had shown previously that deletion of this enzyme seemed as effective as treatment with NSAIDs in models of pain and inflammation.

FitzGerald and his colleagues showed that deletion of mPGES-1, in contrast to deletion or inhibition of COX-2, did not predispose the animals to thrombosis or elevate blood pressure.

Source: University of Pennsylvania School of Medicine, 2006